Insulin Delivery Device Patents Prolong Market Exclusivity

Source link :

Insulin manufacturers are extending brand-name market exclusivity by filing multiple new patents on their products’ delivery devices, a new analysis suggests. The data come from the publicly available US Food and Drug Administration’s (FDA’s) Approved Drug Products With Therapeutic Equivalence Evaluations, dubbed the “Orange Book,” along with Google patents, on all insulin products approved in […]

Author : News Health

Publish date : 2023-11-16 20:36:18

Copyright for syndicated content belongs to the linked Source.